Spevatamig
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Spevatamig, covering 2025-11-04 to 2025-11-04. Get the full timeline:
Most recent: Clinical Trial Update: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) [Phase 1, Phase 2]